Need Help?
Copied to clipboard!

NCTN: Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer (CALGB-40601)

Study ID: CALGB-40601
NCT Number: NCT00770809

Alliance for Clinical Trials in Oncology
Submitted in collaboration with the NCTN/NCORP Data Archive

Trial Title: NCTN: Randomized Phase III Trial of Paclitaxel + Trastuzumab + Lapatinib versus Paclitaxel + Trastuzumab as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer (CALGB-40601)

Trial Description: This randomized phase III trial studies paclitaxel and trastuzumab with or without lapatinib to see how well they work in treating patients with stage II or stage III breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel with trastuzumab and/or lapatinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known which regimen is more effective in treating patients with breast cancer.

Clinical data presented in the following publication(s):


Disease type(s): Breast Neoplasm - Breast Cancer - Invasive

Clinical dataset(s) included:

Additional proteogenomic data are available for this trial under phs003576.
Additional genomic and transcriptomic data are available for this trial under phs001570.

You are encouraged to view the PDF data dictionaries found in the “Documents” tab of the dbGaP study page, which may contain additional information regarding the data or the associated publication(s).